Jyong Biotech (NASDAQ:MENS) Shares Gap Up - Still a Buy?
Jyong Biotech (NASDAQ:MENS) shares opened higher at $33.00 from a previous close of $30.36, last trading at $32.80. Despite the price increase, Weiss Ratings reiterated a 'sell' rating, and the stock has a consensus 'sell' rating. BNP Paribas Financial Markets recently acquired 1,698 shares. Jyong Biotech specializes in plant-derived drugs for urinary system diseases, targeting markets in the U.S., EU, and Asia.
Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report) shares gapped up before the market opened on Wednesday . The stock had previously closed at $30.36, but opened at $33.00. Jyong Biotech shares last traded at $32.80, with a volume of 36,671 shares.
Get Jyong Biotech alerts:
Analyst Ratings Changes
Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of Jyong Biotech in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of "Sell".
Read Our Latest Stock Analysis on Jyong Biotech
Jyong Biotech Price Performance
The stock has a fifty day simple moving average of $48.09.
Hedge Funds Weigh In On Jyong Biotech
A hedge fund recently bought a new stake in Jyong Biotech stock. BNP Paribas Financial Markets bought a new position in Jyong Biotech Ltd. (NASDAQ:MENS - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,698 shares of the company's stock, valued at approximately $67,000.
Jyong Biotech Company Profile
(Get Free Report)OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.
See Also
- Five stocks we like better than Jyong Biotech
- CD Calculator: Certificate of Deposit Calculator
- 5 Stocks to Buy Before Santa Claus Comes to Town
- How to Use High Beta Stocks to Maximize Your Investing Profits
- History Says These are 3 Stocks to Buy for December
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Warner Bros. Sale Rumors Heat Up: What Investors Need to Know
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Jyong Biotech Right Now?
Before you consider Jyong Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jyong Biotech wasn't on the list.
While Jyong Biotech currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
